Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mitochondrial trifunctional protein (TFP) deficiency (TFPD) is a disorder of fatty acid oxidation characterized by a wide clinical spectrum ranging from severe neonatal manifestations including cardiomyopathy, hypoglycemia, metabolic acidosis, skeletal myopathy and neuropathy, liver disease and death to a mild phenotype with peripheral polyneuropathy, episodic rhabdomyolysis and pigmentary retinopathy..
No HPO annotations are available for this condition.
Long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency and trifunctional protein (TFP) deficiency are caused by impairment of mitochondrial TFP. TFP has three enzymatic activities – long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase, and long-chain 3-ketoacyl-CoA thiolase. Deficiency of the enzyme long-chain 3-hydroxyacyl-CoA dehydrogenase occurs in individuals with LCHAD deficiency, while deficiency of all three enzymes occurs in individuals with TFP deficiency. LCHAD and TFP deficiency are disorders of long-chain fatty acid oxidation, which typically present with recurrent episodes of hypoketotic hypoglycemia precipitated by fasting or illness. In addition, the other characteristic manifestations of long-chain fatty acid oxidation defects (FAODs) such as cardiomyopathy, liver dysfunction, or rhabdomyolysis may be present. However, peripheral neuropathy and retinopathy are unique complications of these disorders not seen in other FAODs. The clinical presentation represents a continuous spectrum of severity ranging from severe neonatal-onset to mild late-onset forms. Individuals with LCHAD deficiency usually present with a severe-to-intermediate phenotype, while individuals with TFP deficiency typically present with a severe-to-mild phenotype. Table 2. LCHAD/TFP Deficiency: Frequency of Select Features
No consensus clinical diagnostic criteria for long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency or trifunctional protein (TFP) deficiency have been published.
Suggestive Findings
NBS for LCHAD/TFP deficiency is primarily based on quantification of the analytes 3-hydroxypalmitoyl carnitine (C16-OH) and 3-hydroxyoleoylcarnitine (C18:1-OH) on dried blood spots. C16-OH and C18:1-OH values above the cutoff reported by the screening laboratory are considered positive and require follow-up biochemical testing including plasma acylcarnitine and urine organic acid profiles. If the follow-up biochemical testing supports the likelihood of LCHAD/TFP deficiency, additional testing is required to establish the diagnosis .
No approved treatments are currently available for mitochondrial trifunctional protein deficiency. The disease remains an area of unmet medical need.
A brief outline of treatment recommendations for long-chain fatty acid oxidation defects including long-chain hydroxyacyl-CoA dehydrogenase (LCHAD)/ trifunctional protein (TFP) deficiency has been published . Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with LCHAD/TFP deficiency, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with LCHAD/TFP Deficiency
There are no current published guidelines for surveillance. In addition to regular evaluations by a metabolic specialist and metabolic dietician, the evaluations in are recommended.
Table 9.
Recommended Surveillance for Individuals with LCHAD/TFP Deficiency
Manifestation | Evaluation | Frequency/Comment
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
24 publications have been identified in PubMed for mitochondrial trifunctional protein deficiency. Research spans Case Report / Case Series (29%), Review / Meta-Analysis (17%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 | 29% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:32 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Feature | ~% of Persons w/Feature1 | Comment |
|---|---|---|
presentation | 15% | 39% |
hypoglycemia | 78% | 40% |
dysfunction | 80% | 53% |
Cardiomyopathy | 65% | 63% |
myopathy | 62% | 72% |
neuropathy | 67% | 79% |
Retinopathy | 80% | 12% |
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
Table 3. Genetic Disorders of Interest in the Differential Diagnosis of LCHAD/TFP Deficiency
Gene(s) | Disorder1 | Key Features Overlapping w/LCHAD/TFP Deficiency | Distinguishing Features2 |
|---|---|---|---|
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency | Intermittent hypoketotic hypoglycemia precipitated by fasting or illness; Reye syndrome-like presentation | Absence of myopathy, cardiomyopathy, peripheral neuropathy, retinopathy in MCAD deficiency ACADVL | Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency |
Carnitine palmitoyltransferase 1A (CPT1A) deficiency | Intermittent hypoketotic hypoglycemia liver failure | Absence of peripheral neuropathy retinopathy in CPT1A deficiency CPT2 | Carnitine palmitoyltransferase II (CPT II) deficiency |
Systemic primary carnitine deficiency (CDSP) | Intermittent hypoketotic hypoglycemia precipitated by fasting or illness, skeletal myopathy, cardiomyopathy | Absence of peripheral neuropathy retinopathy in CDSP SLC25A20 | Carnitine-acylcarnitine translocase (CACT) deficiency |
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
Biomarker and diagnostic research for mitochondrial trifunctional protein deficiency has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
decompensation | Consultation w/metabolic physician/biochemical geneticist specialist metabolic dietitian | Consider transfer to specialist center w/experience in mgmt of inherited metabolic diseases.; Blood gas – arterial or venous (e.g. |
General | Referral to clinical geneticist familiar w/LCHAD/TFP deficiency | For implementation of specialized treatment |
Cardiology | Consider cardiology consultation echocardiography | For eval of cardiomyopathy |
Neurology | Consider neurology consultation | For eval of myopathy peripheral neuropathy |
Ophthalmology | Consider ophthalmology consultation | For assessment of vision retinopathy |
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech/language eval Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of LCHAD/TFP deficiency to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with LCHAD/TFP Deficiency Manifestation/Concern | Treatment | Considerations/Other Defect of long-chain fatty acid oxidation |
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
Avoid the following:
Fasting, including periods of preparation and recovery from planned surgery or anesthesia
Inadequate caloric provision during stressors, especially when fasting is involved (surgery or procedure requiring fasting/anesthesia)
Inadequate calories following vaccination
Note: Vaccination is safe.
Dehydration (risk for rhabdomyolysis and acute renal failure)
High-fat diet including ketogenic or carbohydrate-restricted diets for the purpose of weight loss, such as Atkins diet
Administration of intravenous intralipids during an acute metabolic crisis
Anesthetics that contain high doses of long-chain fatty acids (e.g., propofol, etomidate) are avoided in long-chain fatty acid oxidation defects. However, a retrospective analysis revealed no adverse events with propofol for short-duration procedures in individuals with LCHAD/TFP deficiency . A combination of midazolam, thiopental, fentanyl, and remifentanil was used successfully in an individual with LCHAD deficiency .
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
Cardiac transplantation. Favorable outcome after cardiac transplantation in individuals with TFP deficiency has been reported . However, it is expected that with timely diagnosis, strict dietary therapy, and MCT or triheptanoin supplementation, cardiac transplantation may not be required. Bezafibrate is a hypolipidemic drug and an agonist of peroxisome proliferator-activated receptor (PPAR). It increases expression of several enzymes involved in mitochondrial fatty acid oxidation, including TFP . Bezafibrate was reported to have a favorable outcome in two individuals with TFP deficiency . Bezafibrate is not available in the United States. REN001 (Reneo Pharmaceuticals®) is a selective PPAR- agonist that increases transcription of genes involved in mitochondrial fatty acid oxidation.
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
1 trial found
1 yr: weekly to monthly
1-7 yrs: every 1-6 mos
7 yrs: every 6-12 mos
Comprehensive fatty acid profile to assess for essential fatty acid deficiency1 | Annually
Plasma free total carnitine, acylcarnitine profile, CK, AST, ALT | Recommended frequency (by age):
1 yr: every 3 mos
1-7 yrs: every 3-6 mos
7 yrs: every 6-12 mos
| Measurement of head circumference growth | At each visit throughout childhood
| Monitoring of developmental milestones
Neuropsychological testing using age-appropriate standardized assessment batteries
Standardized quality of life assessment tools for affected persons parents/caregivers
| As needed
| EKG echocardiography | Annually or more frequently for severe presentation
| Neurology eval | Annually
NCV EMG | As needed
| Ophthalmology eval | Annually
ERG | Every 2-3 yrs
Source: GeneReviews — "Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency"
Estimated prevalence: Unknown (Unknown prevalence).
Research summaries |
4 |
17% |
Laboratory research | 4 | 17% |
Testing and diagnosis research | 3 | 13% |
Disease patterns and progression | 3 | 13% |
Other research | 1 | 4% |
Clinical study results | 1 | 4% |
New treatment approaches | 1 | 4% |
Balletto G (2026). [PMID: 40820380](https://pubmed.ncbi.nlm.nih.gov/40820380/). *J Child Neurol*. [Review / Meta-Analysis]
Vieira Neto E (2026). [PMID: 41500837](https://pubmed.ncbi.nlm.nih.gov/41500837/). *J Inherit Metab Dis*. [Basic Science / Preclinical]
Vieira Neto E (2026). [PMID: 41948938](https://pubmed.ncbi.nlm.nih.gov/41948938/). *JCI Insight*. [Other]
Preisner F (2026). [PMID: 41626767](https://pubmed.ncbi.nlm.nih.gov/41626767/). *Invest Radiol*. [Diagnostic / Biomarker]
Grünert SC (2026). [PMID: 41554131](https://pubmed.ncbi.nlm.nih.gov/41554131/). *J Inherit Metab Dis*. [Epidemiology / Natural History]
Eke C (2025). [PMID: 40164334](https://pubmed.ncbi.nlm.nih.gov/40164334/). *J Lipid Res*. [Basic Science / Preclinical]
Chung H (2025). [PMID: 40635623](https://pubmed.ncbi.nlm.nih.gov/40635623/). *J Inherit Metab Dis*. [Epidemiology / Natural History]
Castro Casal N (2025). [PMID: 40516853](https://pubmed.ncbi.nlm.nih.gov/40516853/). *Arch Soc Esp Oftalmol (Engl Ed)*. [Case Report / Case Series]
Qaiser F (2025). [PMID: 40790338](https://pubmed.ncbi.nlm.nih.gov/40790338/). *J Peripher Nerv Syst*. [Case Report / Case Series]
Forsyth R (2025). [PMID: 40633017](https://pubmed.ncbi.nlm.nih.gov/40633017/). *Expert Rev Clin Pharmacol*. [Review / Meta-Analysis]
AI-curated news mentioning mitochondrial trifunctional protein deficiency
Updated Aug 3, 2026
Recent research using cardiac MRI has identified myocardial fibrosis and systolic dysfunction in mice deficient in mitochondrial trifunctional protein. These findings may provide insights into the cardiac implications of mitochondrial disorders.